|
 |
CinacalcetThis page contains recent news articles, when available, and an overview of Cinacalcet but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Results of an open-label extension study reveal favorable biochemical and bone densitometric outcomes with cinacalcet therapy for up to 5.5 years in ... Endocrine Today Cinacalcet Effective for Refractory Hyperparathyroidism - Nov 1, 2009 Cinacalcet showed long-term efficacy in reducing serum parathyroid hormone (PTH) and calcium levels in renal transplant patients with refractory tertiary ... Renal and Urology News Cinacalcet May Aid in Bone Remodeling After Renal Transplantation - Oct 29, 2009 The indication for cinacalcet therapy was persisting hyperparathyroidism and declining renal function as well as nephrocalcinosis in transplant biopsy. ... Renal and Urology News Vitamin D Insufficiency Common in Dialysis Patients with Secondary ... - Oct 30, 2009 The study included 3793 HD patients with secondary hyperparathyroidism participating in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular ... Renal and Urology News NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance - Nov 4, 2009 NPS earns royalties on (i) Amgen's sales of Sensipar ® (cinacalcet HCl), (ii) Nycomed's sales of Preotact ® (parathyroid hormone 1-84 [rDNA origin] ... WELT ONLINE Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to ... - Oct 21, 2009 Worldwide sales of Sensipar(®) (cinacalcet) increased 2 percent to $165 million in the third quarter of 2009 versus $161 million during the third quarter of ... Reuters Amgen 3Q Profit Up 24% - Oct 22, 2009 ...(cinacalcet) increased 2 percent to $165 million in the third quarter of 2009 versus $161 million during the third quarter of 2008, primarily as a result of ... The FINANCIAL NPS Pharma says Cinacalcet gets approval in Japan - Oct 25, 2007 Oct 25 (Reuters) - NPS Pharmaceuticals Inc (NPSP.O) said Japanese health regulators approved its drug, cinacalcet hydrochloride, for the treatment of ... Reuters Cinacalcet should be used to treat secondary hyperparathyroidism in … - Mar 11, 2008 Secondary hyperparathyroidism (SHPT) is a serious and progressive disease that begins early in the course of chronic kidney disease (CKD). ... Nature.com Cinacalcet should not be used to treat secondary hyperparathyroidism... - Feb 7, 2008 Use of the calcimimetic cinacalcet to treat secondary hyperparathyroidism (SHPT) in non-dialysis-dependent patients with chronic kidney disease (CKD) is ... Nature.com … with MEN1-associated hyperparathyroidism, responsive to cinacalcet - Dec 19, 2007 Cinacalcet could represent an important pharmacological intervention in ... (B) After 1 year of treatment with cinacalcet the echographic lesion was ... Nature.com Does cinacalcet safely and effectively maintain long-term PTH control... - Oct 28, 2005 Moe SM et al. (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20: 2186–2193 PubMed ... Nature.com … Impact of Sensipar(R)/Mimpara(R) (Cinacalcet HCl) on Mortality an - Jul 16, 2006 EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events)(TM) ... At ERA-EDTA, Amgen also announced new cinacalcet HCl data from the OPTIMA ... RedOrbit … of parathyroid carcinoma with hypercalcemia responsive to cinacalce... - Nov 29, 2005 Cinacalcet therapy (in the doses indicated in the inset) was started on treatment day 35. ... The patient was treated with CINACALCET, 60 mg orally daily, ... Nature.com Optimal paricalcitol starting dose for parathyroid hormone suppression... - Jan 30, 2007 Regarding cinacalcet, we would recommend the concomitant use of this agent not with paricalcitol or calcitriol, but rather with CaCO3 as a phosphate binder. ... Nature.com … Better With Paricalcitol Alone Than Combined With Cinacalcet - Apr 3, 2008 ..."This historical study indicates that the role of cinacalcet can be an ... Of these, 8426 patients were treated with paricalcitol and/or cinacalcet and ... Medscape Cinacalcet hydrochloride (Sensipar).(Pharmacology Notes)(Drug … - Apr 1, 2005 Currently, >300000 patients with end-stage renal disease require dialysis. Secondary hyperparathyroidism is a serious complication of end-stage renal ... Free with registration - Baylor University Medical Center... - AccessMyLibrary.com Earlier Use of Cinacalcet Provides Better Parathyroid Hormone Control - Jul 28, 2006 July 28, 2006 (Glasgow, Scotland) -- Data from the Open-Label, Randomized Study Using Cinacalcet To Improve Achievement of KDOQI Targets in Patients with ... Medscape Treating hyperparathyroidism with cinacalcet HCl (Sensipar[R]).(Clinic... - May 1, 2007 Q: We are currently giving some of our patients on dialysis cinacalcet HCl (Sensipar[R]) for the treatment of hyperparathyroidism (HPT). ... Free with registration - Nephrology Nursing Journal - AccessMyLibrary.com Cinacalcet (Systemic). - Jul 28, 2005 Cinacalcet ( sin-a-KAL-set) is a medicine used to treat hyperparathyroidism in patients with chronic kidney disease who are on dialysis. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Cinacalcet lowers body's 'set point' to control hyperparathyroidism... - Jul 21, 2008 New technique could eliminate inherited mitochondrial disease — [26 Aug 2009] — Researchers have developed an experimental technique with the potential to ... Science Centric Learn about Cinacalcet from Consumer Reports Health. - Jan 4, 2005 Cinacalcet is used alone or with other medications to treat secondary hyperparathyroidism (a condition in which the body produces too much parathyroid ... consumerreports.org Cinacalcet reduced serum calcium in hemodialysis patients with … - Sep 10, 2008 In hemodialysis patients with secondary hyperparathyroidism, cinacalcet (Sensipar, Amgen), a calcimimetic, may increase the parathyroid's sensitivity to ... Endocrine Today Cinacalcet Helps Dialysis Patients Achieve KDOQI Targets - Jun 25, 2007 June 25, 2007 (Barcelona) — The calcimimetic agent cinacalcet counteracts secondary hyperparathyroidism (SHPT) and improves calcium and phosphorous ... Medscape NICE Recommends Mimpara® (cinacalcet) For The Treatment Of A … - Nov 7, 2006 The National Institute for Health and Clinical Excellence (NICE) has released a positive Final Appraisal Document (FAD) in support of the use of Mimpara® ... Medical News Today - Medical News Today (press release) Cinacalcet Proves Ineffective for Primary Hyperparathyroidism, … - Jun 20, 2008 By Bryan DeBusk, PhD. SAN FRANCISCO -- June 20, 2008 -- Cinacalcet, as an alternative to parathyroid surgery, failed to show relief of primary ... DG News Cinacalcet May Improve PTH Control - Apr 19, 2007 April 19, 2007 (Orlando) — Cinacalcet, a calcimimetic that inhibits parathyroid hormone (PTH) release from the parathyroid gland, may improve PTH control in ... Medscape The role of cinacalcet in treating secondary hyperparathyroidism.(Issu... - Mar 1, 2005 The challenge for clinicians to manage secondary hyperparathyroidism (HPT) and improve patient outcomes is apparent in light of a continuously growing ... $4.95 - Nephrology Nursing Journal - ECNext NPS shares plummet 39% - May 4, 2006 In 2004, the company's cinacalcet HCI was approved by the FDA to treat secondary hyperparathyroidism; NPS licensed the drug to Amgen Inc., which sells it as ... $2.95 - Deseret News - NewsBank HCI Capital AG acquires a minority stake in Aragon AG - Dec 31, 2006 ... - Dec 15, 2006 Amgen's cinacalcet hydrochloride (HCI), a treat ment for some…for Amgen's cinacalcet hydrochloride (HCI), a treat ment for some…for Amgen's cinacalcet ... Pay-Per-View - deals - Alacra Store Cinacalcet improves outcomes in HPT - Nov 1, 2005 London, UK - Cinacalcet (Sensipar, Amgen)?a calcimimetic agent used to treat secondary hyperparathyroidism (HPT)?has been shown to reduce the risk of ... Medscape Cinacalcet Effective for Hypercalcemia in Parathyroid Cancer - Sep 24, 2007 NEW YORK SEPT 24, 2007 (Reuters Health) - Cinacalcet effectively lowers serum calcium concentrations in patients with inoperable parathyroid carcinoma, ... Cancerpage.com Cinacalcet Lowers Parathyroid Cancer-Related Hypercalcemia - Nov 6, 2007 By David Douglas. NEW YORK NOV 06, 2007 (Reuters Health) - The calcimimetic, cinacalcet HCl, reduces the serum calcium concentration in inoperable ... Cancerpage.com NPS files for drug approval, but announces slow quarter - May 11, 2005 During the first quarter of 2004, the company received milestone payments of $10 million from Amgen for the approval of the cinacalcet and $2 million from ... $2.95 - Salt Lake Tribune, The - NewsBank Earlier Intervention With Sensipar/Mimpara Improved Ability To... - Jul 24, 2006 EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events)(TM) is a Phase 3 ... Cinacalcet HCl is marketed as Sensipar in the United States, ... Medical News Today - Medical News Today (press release) NPS Pharmaceuticals Notified of ANDA Filings for Cinacalcet HCl - Jun 16, 2008 NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the receipt of Paragraph IV Certification Notice Letters related to certain drug manufacturers' ... RedOrbit Event Brief of Q3 2006 NPS Pharmaceuticals Earnings Conference Call -... - Nov 8, 2006 YTD cinacalcet sales were $223m, 109% increase over the same period in 2005. ... s partner for cinacalcet HCl in the Far East, filed for approval to market ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com The role of cinacalcet in treating secondary hyperparathyroidism.(Issu... - Mar 1, 2005 The role of cinacalcet in treating secondary hyperparathyroidism.(Issues in Renal Nutrition: Focus on Nutritional Care for Nephrology Patients) ... find ... Pay-Per-View - Nephrology Nursing Journal - HighBeam Research … : NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in... - Oct 25, 2007 NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Amgen Announces EVOLVE Trial(TM) and Gilead Sciences to Release … - Jul 18, 2006 EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events)(TM) is a Phase 3 international, clinical outcomes study designed to determine ... Free with registration - M2 Presswire - AccessMyLibrary.com IN BRIEF: No special reporting for cinacalcet.(Brief article) - Sep 1, 2007 The special reporting directive is no longer required for cinacalcet (Mimpara, Amgen). The treatment is used in end-stage renal disease patients on dialysis ... Free with registration - Chemist & Druggist - AccessMyLibrary.com Drug Lowers Body's 'Set Point' to Control Hyperparathyroidism in... - Jul 11, 2008 Newswise — A medication called cinacalcet—an important part of treatment to control high ... Cinacalcet is one of a family of drugs called calcimimetics. ... newswise.com NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating … - Feb 16, 2006 The cost of royalties consists of royalties owed under our agreement with the Brigham and Women's Hospital on sales of cinacalcet HCl. ... $4.95 - PR Newswire - ECNext Japan OKs cinacalcet for CKD patients. - Nov 5, 2007 New Jersey, USA-based biopharmaceutical firm NPS Pharmaceuticals says that Japan's Pharmaceuticals and Medical Devices Agency has approved its drug, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Drug lowers body's 'set point' to control hyperparathyroidism in... - Jul 17, 2008 A medication called cinacalcet—an important part of treatment to control high levels of ... Cinacalcet is one of a family of drugs called calcimimetics. ... Eureka! Science News NPS Pharmaceuticals to Webcast Presentation at Jefferies Life... - Jun 21, 2006 The company has two products on the market, cinacalcet HCl in the US and Europe, and PREOTACT(R) in Europe. The company also has drug candidates in various ... Free with registration - PR Newswire - AccessMyLibrary.com Abstract and Introduction - Jul 9, 2007 The follow-up period was 9 months before and after the introduction of cinacalcet. We started by adding 30 mg of cinacalcet orally once daily to their ... Medscape The new role of calcimimetics as vasculotropic agents - Sep 12, 2008 9 The failure of cinacalcet to reduce calcification in this study is probably due ... Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, ... Nature.com Press Release: NPS Pharmaceuticals Reports Second Quarter and Six … - Aug 3, 2006 Article: Amgen Submitted New Drug Application for Cinacalcet ... ... Cinacalcet HCl is an oral compound with a ... reduction in the levels of parathyroid ... Pay-Per-View - PR Newswire - HighBeam Research IN BRIEF: No special reporting for cinacalcet. - Sep 1, 2007 IN BRIEF: No special reporting for cinacalcet. The special reporting directive is no longer required for cinacalcet (Mimpara, Amgen). ... $9.94 - Chemist & Druggist - Alacra Store IN BRIEF: No special reporting for cinacalcet.(Brief article) - Sep 1, 2007 The special reporting directive is no longer required for cinacalcet (Mimpara, Amgen). The treatment is used in end-stage renal disease patients on dialysis ... $4.95 - Chemist & Druggist - ECNext Heart Disease; Reports from Japan, Denmark and the United States … - Oct 23, 2006 Cinacalcet treatment enables a significant number of patients to achieve the ... "Clinical trials have shown that cinacalcet significantly reduced the risks ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating … - Mar 8, 2005 Cinacalcet HCl * Cinacalcet HCl is the first NPS molecule to reach the marketplace. In April 2004, Amgen launched Sensipar(R) (cinacalcet HCl) for the ... $4.95 - PR Newswire - ECNext NICE recommends Mimpara with caveats.(National Institute for Health … - Jan 29, 2007 ...oral calcimimetic, Mimpara (cinacalcet), in the treatment of secondary hyperparathyroidism in end-stage renal disease on maintenance dialysis therapy. ... $4.95 - Pharma Marketletter - ECNext 血液ä¸å?«é’™é«˜å?¯è‡´å‰?列腺癌 - Sep 4, 2008 ...已有è?¯ç‰©å¦‚å?ˆå??为骨化三醇的罗钙全（calcitriol）ã€?多西骨化醇(doxercalciferol)ã€? 帕利骨化醇(paricalcitol)和西那å?¡å¡ž(cinacalcet)ç‰å?¯ä»¥é™?低血液ä¸é’™çš„å?«é‡?。 ... 环ç?ƒç½‘ Press Release: NPS Pharmaceuticals Reports Fourth Quarter and Year- … - Mar 8, 2005 Cinacalcet HCl * Cinacalcet HCl is the first NPS molecule to reach the marketplace. In April 2004, Amgen launched Sensipar(R) (cinacalcet HCl) for the ... Pay-Per-View - PR Newswire - HighBeam Research New Treatment Option For Life-Threatening Symptom Of Parathyroid … - Sep 10, 2007 ...“Cinacalcet offers an important option for treating hypercalcemia in patients with ... Cinacalcet is a drug that mimics how calcium acts on organ tissues. ... sciencedaily.com New Treatment Option For Life Threatening Symptom Of Parathyroid … - Sep 8, 2007 ..."Cinacalcet offers an important option for treating hypercalcemia in patients with ... Cinacalcet is a drug that mimics how calcium acts on organ tissues. ... Medical News Today - Medical News Today (press release) Netherlands Corporate News - New Data at ERA-EDTA Show Mimpara … - Dec 5, 2008 BW)(CA-AMGEN) New Data at ERA-EDTA Show Mimpara(R) (Cinacalcet) Improves Management of Secondary Hyperparathyroidism in Daily Clinical Practice Business ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Lanzamiento en España del cinacalcet para el hiperparatiroidismo … - Jul 14, 2005 La compañÃa biotecnológica Amgen ha iniciado la comercialización en España de Mimpara (cinacalcet), primer agente calcimimético aprobado en Europa y Estados ... doyma.es Sensipar® No Longer Indicated for Chronic Kidney Disease Patients ( … - Jun 27, 2007 The clinical development program investigating cinacalcet for the treatment of secondary hyperparathyroidism (HPT) in patients with CKD not receiving ... DG News Guidelines for disorders of mineral metabolism and secondary … - Jan 13, 2006 Cinacalcet has been definitively shown to lower PTH concentrations in dialysis ... 26 The biochemical effects of cinacalcet (simultaneous decreases in PTH, ... Nature.com Cinacalcet obtiene la aprobación de la Comisión Europea para ampliar... - Jul 2, 2008 Autorización basada en la evaluación positiva de riesgos y beneficios en pacientes con hipercalcemia por hiperparatiroidismo primario para los que la ... acceso.com Event Brief of Q1 2006 NPS Pharmaceuticals Earnings Conference Call -... - May 2, 2006 Kirin has development and marketing rights to cinacalcet HCL in Japan, Korea, ... Amgen, which has the North American and European rights to cinacalcet HCL ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Amgen launches further CV endpoint in EVOLVE, the largest ever Ph III... - Jul 24, 2006 EVOLVE (Evaluation of cinacalcet therapy to lower cardiovascular events) is a double-blind, placebo-controlled trial which will enrol 3800 patients with CKD ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Netherlands Corporate News - Mimpara Receives European Commission … - Jun 24, 2008 BW)(AMGEN) Mimpara(R) (cinacalcet) Receives European Commission Approval for ... About Mimpara Mimpara(R) (cinacalcet) (also known as Sensipar(R) in the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Finance; NPS Pharmaceuticals reports net loss for the fourth quarter... - Mar 14, 2006 The cost of royalties consists of royalties owed under our agreement with the Brigham and Women's Hospital on sales of cinacalcet HCl. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones NPS Pharmaceuticals Reports Third Quarter and Nine Month Results. - Nov 4, 2005 ...royalty revenue from Amgen on increased sales of cinacalcet HCl and due to ... sales of cinacalcet HCl due to Amgen's achievement of certain cumulative ... $4.95 - PR Newswire - ECNext Netherlands Corporate News - Mimpara Receives Positive CHMP … - Apr 25, 2008 BW)(AMGEN) Mimpara(R) (Cinacalcet) Receives Positive CHMP Opinion for Extension ... About Mimpara Mimpara(R) (cinacalcet) (also known as Sensipar(R) in the ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Article: GenData, Amgen to begin collaborative research - Deseret... - Jan 6, 2005 Deseret News (Salt Lake City); March 15, 2004 ; 700+ words ... ... compound (cinacalcet HCl) is licensed to Amgen (Nasdaq: AMGN) and will be marketed . ... Pay-Per-View - Deseret News - HighBeam Research 'Creatinine Is The New Cholesterol' For Detecting Vascular Risks Of … - Jul 22, 2006 A recently-introduced treatment called cinacalcet HCl, marketed by Amgen as Mimpara or ... The EVOLVE trial (Evaluation Of cinacalcet HCl therapy to Lower ... Medical News Today - Medical News Today (press release) Event Brief of Q1 2007 NPS Pharmaceuticals Earnings Conference Call -... - May 9, 2007 The growth in Cinacalcet royalty payments reflects the 72% increase in ... The Cinacalcet royalty revenue is currently committed to pay interest and repay ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com SPECIAL REPORT: Blood testing diagnostic for parathyroid disease.( … - Mar 26, 2007 Cinacalcet was approved in January 2007 by NICE as a treatment for patients with secondary ... Patients who receive cinacalcet should have regular checks. ... Free with registration - The Practitioner - AccessMyLibrary.com NPS Pharmaceuticals Reports Second Quarter and Six Month Operating … - Aug 3, 2006 In the second quarter of 2006 NPS recognized increased royalty revenue from sales of Sensipar(R)/Mimpara(R) (cinacalcet HCl) by Amgen, celebrated the ... Free with registration - PR Newswire - AccessMyLibrary.com Article: Buying Amgen stock worth considering - Deseret News (Salt... - Mar 2, 2008 California-based Amgen seeks approval from the U.S. Food and Drug Administration to market cinacalcet HCl ... license agreement with Amgen, NPS will receive ... Pay-Per-View - Deseret News - HighBeam Research Press Release: NPS Pharmaceuticals Reports Third Quarter and Nine … - Nov 4, 2005 ...royalty revenue from Amgen on increased sales of cinacalcet HCl and due to ... sales of cinacalcet HCl due to Amgen's achievement of certain cumulative ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q1 2005 NPS Pharmaceuticals Earnings Conference Call -... - May 10, 2005 A $10m milestone payment from Amgen for the approval of the Cinacalcet NDA by the FDA in March 2004. 2. A $2m milestone payment from Kirin Brewery for the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) $250.00 - Revere Reports - Revere NPS Pharmaceuticals Reports First Quarter 2006 Operating Results. - May 2, 2006 Kirin has filed a new drug application (NDA) with the Japanese Pharmaceutical and Medical Devices Agency for clearance to market cinacalcet HCl in Japan for ... $4.95 - PR Newswire - ECNext Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Mimpara. - Jan 29, 2005 Cinacalcet is metabolised in part by CYP3A4. Concomitant use of a strong inhibitor of CYP3A4 such as ketoconazole can almost double cinacalcet levels. ... $9.94 - Chemist & Druggist - Alacra Store Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) $250.00 - Revere Reports - Revere Amgen's Mimpara sees good HRQoL data.(health-related quality of life... - Oct 10, 2005 A new study published in the October issue of Kidney International shows positive results for US biotechnology giant Amgen's Mimpara (cinacalcet) in the ... $4.95 - Pharma Marketletter - ECNext Mimpara.(Brief Article) - Jan 29, 2005 Cinacalcet is metabolised in part by CYP3A4. Concomitant use of a strong inhibitor of CYP3A4 such as ketoconazole can almost double cinacalcet levels. ... $4.95 - Chemist & Druggist - ECNext Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Sensipar (Cinacalcet Hydrochloride). Phase I/Phase II Clinical Stage Products ... Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride) ... $250.00 - Revere Reports - Revere Control del hiperparatiroidismo de pacientes en diálisis - Jul 18, 2008 El cinacalcet, fármaco que se utiliza para controlar las concentraciones ... El estudio aporta nuevos datos sobre cómo el cinacalcet y otros fármacos ... Intramed.net - Intramed.net (Suscripción) Article: U. professor honored for dialysis research - Deseret News... - May 10, 2005 A report, 'Change in coronary artery calcification score due to cinacalcet hydrochloride administration,' is newly published data in Therapeutic Apheresis ... Pay-Per-View - Deseret News - HighBeam Research Surgery for obesity may cure diabetes | Article from Deseret News... - Jan 23, 2008 Cinacalcet HCl was discovered by NPS as a possible drug ... cinacalcet HCl if the drug is cleared by the FDA for use in the United States. ... Pay-Per-View - Deseret News - HighBeam Research FDA agrees to review Preos drug application | Article from Deseret... - Jul 12, 2005 Calif., had submitted a new drug application (NDA) to the U.S. Food and Drug Administration seeking approval to market cinacalcet HCl as a therapy for ... Pay-Per-View - Deseret News - HighBeam Research Supplement industry may challenge FDA rules on ad claims. | Article... - Dec 11, 2005 Calif., is seeking approval from the FDA to market cinacalcet HCl as a drug to treat ... NPS will receive $6 million based on the FDA filing. ... Pay-Per-View - Salt Lake Tribune, The - HighBeam Research A patient with persistent primary hyperparathyroidism due to a second... - Aug 2, 2006 8 The calcimimetic cinacalcet lowered PTH concentrations and normalized serum ... (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in ... Nature.com NPS Pharmaceuticals Reports 2006 Results and Progress, Announces … - Mar 14, 2007 Cinacalcet HCl * In February 2007, NPS partner Amgen, Inc. reported 2006 Sensipar(R) (cinacalcet HCl) sales of $321.8 million, approximately 100% higher ... Free with registration - PR Newswire - AccessMyLibrary.com Managing ESRD following MI.(Clinical Twisters)(end-stage renal... - Jun 20, 2005 Cinacalcet (Sensipar, Amgen) might be an option for C.C. to help control PTH. However, I'd make sure that vitamin D and phosphate binder therapy are ... Free with registration - Drug Topics - AccessMyLibrary.com Event Brief of Q2 2006 NPS Pharmaceuticals Earnings Conference Call -... - Aug 3, 2006 In their quarterly call, Amgen announced that they had initiated a Phase 3 trial to evaluate the potential for Cinacalcet therapy to lower cardiovascular ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com NPS Pharmaceuticals Reports Third Quarter 2008 Financial Results and ... - Nov 5, 2008 NPS recognized royalty revenue on Amgen's sales of Sensipar(R) (cinacalcet HCl) of $19.0 million for the third quarter of 2008, as compared to $14.3 million ... Genetic Engineering News - Genetic Engineering News (press release) NPS Pharmaceuticals Reports Second Quarter Financial Results - Aug 7, 2008 ...(ii) royalty revenue on Amgen's sales of Sensipar(R) (cinacalcet HCl), (iii) revenues associated with the company's agreement with Nycomed for ... Genetic Engineering News - Genetic Engineering News (press release) The Bellwether Report Investigates the recent market correction for... - May 3, 2006 ...in royalty revenue earned from Amgen on the sales of cinacalcet HCl of and a ... cinacalcet HCl marketing approval with the Japanese regulatory agency." ... $4.95 - M2 Presswire - ECNext Merger and Acquisition Scenario - Sep 6, 2008 Target. Gattex (Teduglutide); Sensipar (Cinacalcet Hydrochloride); Preos (Human Parathyroid Hormone); 751689 (Ronacaleret) ... $250.00 - Revere Reports - Revere Competitors by Product Report - Apr 14, 2007 NPS Pharmaceuticals, Inc. (NPSP) Products:. Preos (Human Parathyroid Hormone); Sensipar (Cinacalcet Hydrochloride). OrthoLogic Corporation (OLGC) Products: ... $75.00 - Revere Reports - Revere |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
